TST. TST represents and warrants to Brokat that the following statements are correct and complete as of the date of this Agreement and will be correct and complete as of the Closing Date (as though made then and as though the Closing Date were substituted for the date of this Agreement throughout this Article IV) subject only to the exceptions described in the attached Disclosure Schedule:
TST. QFT-GIT agreement has been assessed in a number of different diseased populations, including rheumatoid arthritis patients (Xxxxx, Zapantis, Xxxxxxx, & Xxxxxxxxx, 2015; Xxx et al., 2014), kidney transplant recipients (Xxxxxxxxxx et al., 2017; Xxxxx et al., 2017; Xxxxxxxx et al., 2017), and people living with HIV infection (Xxxxx et al., 2016; Xxxxxx et al., 2016; Xxxxxx, Xxxxx- Xxxxx, Xxxxxxx, & Xxxxxx, 2016; Xxxxxxxxxx et al., 2016; Xxxxxxx, Xxxxxxxxxx, Xxxxxxx, & Xxxxxxxx, 2014; Xxxxxxxxxxxxxx et al., 2013). A 2015 review by Xxxxxxx, xx.xx, identified 13 studies performed among HIV-infected patients, both adults and children (Xxxxxxx et al., 2014). Discordance ranged from 11.0% to 79.0% and kappa ranged from 0.30 to 0.60. Other studies performed in people living with HIV infection since the above review have shown varying rates of discordance/kappa: [?%/0.29, n=240 (Chkhartishvili et al., 2013)], [26.1%/0.08, n=130 (Khazraiyan et al., 2016)], [14.2%/0.20, n=110 (Xxxxx et al., 2016)], [25%/0.25, n=252 (Xxxxxx et al., 2016)], and [11.6%/0.20, n=140 (Xxxxxx et al., 2016)].
TST. QFT-GIT agreement in children has also been assessed (Xxxxxx et al., 2015; Xxxx et al., 2015; Xxxxxxx Xxx, Xxxxxxx, Xxxxxxxxx, & Xxxxxx, 2015). Discordance/kappa from these studies was determined as follows: [23.1%/0.20, n=2,520 immigrant children from Mexico, the Philippines, and Vietnam (Xxxxxx et al., 2015)], [20.0%/0.58, n=103 children from a pediatric clinic (Rose et al., 2015)], and [5.8%/0.01, n=967 children randomly sampled from schools (Masoumi Asl et al., 2015)]. Studies that are the most comparable to this present study are those performed in healthy (non-HCW or non-contact) subjects. Xxxxx’x 2015 systematic review and meta-analysis included data from 22 studies comparing TST and QFT-GIT in healthy populations (Xxxxx et al., 2015). The reported overall kappa of 0.35 was slightly lower than the overall kappa of 0.40 found in their assessment of agreement in TB contacts. In an assessment of 60 healthy subjects in Thailand, a discordance/kappa of 25.0%/0.16 was found (Reechaipichitkul, Pimrin, Bourpoern, Prompinij, & Xxxxxx, 2015). In 107 healthy, male, Ethiopian medical and paramedical students, discordance/kappa was 8.4%/0.83 (Xxxxxx et al., 2012). In one small (n=207) population-based study conducted along the U. S. Mexico border, Xxxx, xx.xx, found a discordance/kappa of 26.1%/0.39, (Xxxx et al., 2015). In another (larger) population-based study which examined TST – QFT-GIT agreement in the National Health and Nutrition Examination (NHANES) Survey, Ghassemieh, xx.xx, determined a discordance/kappa of 3.0%/0.27 among U. S.-born and 18.4%/0.38 among foreign-born in this large, population-based sample of 6,064 subjects (Ghassemieh et al., 2016). In this NHANES study, QFT-GIT and TST were performed on the same day, as was the case in this present study.
TST. QFT-GIT agreement, by comparing results of TST and QFT-GIT that were initiated on the same day.
TST expressly warrants and represents that it owns all of the rights, title and interest in and to the Licensed Patents, except for U.S. Patent No. 5,856,646 which it jointly owns with Xxxxx-Xxxxxxx Company, LLC.
TST. 22 Sumitomo: ---------------------- ---------------------- ----------------------
TST. 003 Seven will perform testing on an agreed-to list of Devices and Phones supported by Sprint. TST.004 Seven agrees that all new Seven Personal Edition Releases, Software downloads or Software Releases will be compatible with the previous sequential release of Sprint Seven Personal Edition and vice versa for a period of at least [* * *]. Past this [* * *] period, Sprint will require its users to upgrade to a specific release, if for some reason, SEVEN requires such change to effectively support users of System SEVEN Personal Edition.
TST. 001 Supplier will perform both structured, scripted feature tests and unstructured tests on Supplier Service prior to delivery to Sprint.
TST. 002 Supplier will participate in a formal testing review process by Sprint to ensure quality and integrity of results.
TST. 003 Supplier will perform testing on Devices as outlined in section 8C of the Contract Order.
